TFAP4 is a positive prognosis factor in B-ALL. (A) Plot showing normalized MYC and TFAP4 expression from 104 B-ALL patient samples in the TARGET phase 2 study. (B-C) Survival analysis of deceased patients with high vs low TFAP4 expression among patients with high MYC expression (z score >2; TFAP4^lo median survival, 1413 days; TFAP4^hi median survival, undefined). (D) Normalized ERG expression from B-ALL patient samples in (B). RNA-seq, RNA sequencing.